Total Valuation
vTv Therapeutics has a market cap or net worth of €110.21M. The enterprise value is €380.57.
Market Cap€110.21M
Enterprise Value€380.57
Share Statistics
vTv Therapeutics has 3,953,928 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,953,928
Owned by Insiders11.48%
Owned by Institutions19.37%
Financial Efficiency
vTv Therapeutics’s return on equity (ROE) is -0.42 and return on invested capital (ROIC) is -39.41%.
Return on Equity (ROE)-0.42
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-39.41%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-1.20M
Employee Count26
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of vTv Therapeutics is ―. vTv Therapeutics’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio5.23
Price to Fair Value5.23
Price to FCF-13.34
Price to Operating Cash Flow-23.69
PEG Ratio0.00
Income Statement
In the last 12 months, vTv Therapeutics had revenue of 0.00 and earned -26.97M in profits. Earnings per share was -3.20.
Revenue0.00
Gross Profit0.00
Operating Income-32.81M
Pretax Income-31.08M
Net Income-26.97M
EBITDA-31.06M
Earnings Per Share (EPS)-3.20
Cash Flow
In the last 12 months, operating cash flow was -16.76M and capital expenditures 0.00, giving a free cash flow of -16.76M billion.
Operating Cash Flow-16.76M
Free Cash Flow-16.76M
Free Cash Flow per Share-4.24
Dividends & Yields
vTv Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.12
52-Week Price Change97.10%
50-Day Moving Average28.34
200-Day Moving Average28.84
Relative Strength Index (RSI)47.68
Average Volume (3m)0.00
Important Dates
vTv Therapeutics upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
vTv Therapeutics as a current ratio of 13.54, with Debt / Equity ratio of 0.00%
Current Ratio13.54
Quick Ratio13.54
Debt to Market Cap0.00
Net Debt to EBITDA2.86
Interest Coverage Ratio-5.47K
Taxes
In the past 12 months, vTv Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
vTv Therapeutics EV to EBITDA ratio is -7.98, with an EV/FCF ratio of -9.82.
EV to Sales0.00
EV to EBITDA-7.98
EV to Free Cash Flow-9.82
EV to Operating Cash Flow-9.82
Balance Sheet
vTv Therapeutics has €86.64M in cash and marketable securities with €0.00 in debt, giving a net cash position of €86.64M billion.
Cash & Marketable Securities€86.64M
Total Debt€0.00
Net Cash€86.64M
Net Cash Per Share€21.91
Tangible Book Value Per Share€7.65
Margins
Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin100.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for vTv Therapeutics is €49.92, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€49.92
Price Target Upside87.69% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast197478.27%
EPS Growth Forecast76.91%